Evaluation of Rhesus Rotavirus Monovalent and Tetravalent Reassortant Vaccines in US Children
暂无分享,去创建一个
R. Glass | M. Pichichero | M. Rennels | D. Bernstein | J. Camardo | D. Sack | R. Ward | M. Levin | G. Rodgers | Y. Maldonado | J. Cherry | E. Wald | M. Jackson | G. Rodgers | E. Anderson | L. Pickering | E. Guzman | P. Dennehy | G. Rabalais | H. Froehlich | A. Pomeranz | S. Chartrand | B. L. Davidson | E. Zito | Kyung-Hee Kim | S. Fries | D. Blumberg | V. Keane | J. Forro | F. Pedreira | D. Said | E. Starr | B. L. Davidson | R. Imrie | M. Mack | C. W. Hamm | N. Singh-Naz | R. V. Dyke
[1] A. Kapikian,et al. Reactogenicity and immunogenicity of a high-titer rhesus rotavirus-based quadrivalent rotavirus vaccine , 1993, Journal of clinical microbiology.
[2] D. Bernstein,et al. Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children , 1993, Journal of virology.
[3] T. Vesikari,et al. Safety and immunogenicity of oral tetravalent human-rhesus reassortant rotavirus vaccine in neonates. , 1992, The Pediatric infectious disease journal.
[4] D. Sack,et al. Evidence that protection against rotavirus diarrhea after natural infection is not dependent on serotype-specific neutralizing antibody. , 1992, The Journal of infectious diseases.
[5] M. Pichichero,et al. Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. The Elmwood, Panorama, and Westfall Pediatric Groups. , 1992, The Journal of infectious diseases.
[6] T. Vesikari,et al. Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity. , 1992, The Pediatric infectious disease journal.
[7] D. Sack,et al. Culture adaptation and characterization of group A rotaviruses causing diarrheal illnesses in Bangladesh from 1985 to 1986 , 1991, Journal of clinical microbiology.
[8] R. Glass,et al. Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral polio vaccine. , 1991, American journal of diseases of children.
[9] R. Sack,et al. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population. , 1991, The Journal of infectious diseases.
[10] D. Bernstein,et al. Evaluation of WC3 Rotavirus Vaccine and Correlates of Protection in Healthy Infants , 1990 .
[11] S. Plotkin,et al. Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3. , 1990, The Journal of infectious diseases.
[12] M. Rennels,et al. An efficacy trial of the rhesus rotavirus vaccine in Maryland. The Clinical Study Group. , 1990, American journal of diseases of children.
[13] E. Mackow,et al. Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implications for vaccine development. , 1990, The Journal of infectious diseases.
[14] M. Vilar,et al. Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants , 1990, Journal of clinical microbiology.
[15] A. Kapikian,et al. Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine , 1990, Journal of Medical Virology.
[16] H. Greenberg,et al. Extramucosal spread and development of hepatitis in immunodeficient and normal mice infected with rhesus rotavirus , 1990, Journal of virology.
[17] D. Bernstein,et al. Induction and persistence of local rotavirus antibodies in relation to serum antibodies , 1989, Journal of medical virology.
[18] R. Glass,et al. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. , 1989, The Journal of infectious diseases.
[19] M. Vilar,et al. Reactions to and antigenicity of two human-rhesus rotavirus reassortant vaccine candidates of serotypes 1 and 2 in Venezuelan infants , 1989, Journal of clinical microbiology.
[20] R. Glass,et al. Rotavirus as a cause of diarrheal morbidity and mortality in the United States. , 1988, The Journal of infectious diseases.
[21] S. Plotkin,et al. Protective Effect of WC3 Vaccine Against Rotavirus Diarrhea in Infants During a Predominantly Serotype 1 Rotavirus Season , 1988, The Journal of infectious diseases.
[22] M. Pichichero,et al. Field trial of rhesus rotavirus vaccine in infants. , 1988, The Pediatric infectious disease journal.
[23] R. Edelman. Perspective on the development and deployment of rotavirus vaccines. , 1987, The Pediatric infectious disease journal.
[24] P. Byass,et al. TRIAL OF AN ATTENUATED BOVINE ROTAVIRUS VACCINE (RIT 4237) IN GAMBIAN INFANTS , 1987, The Lancet.
[25] K. Taniguchi,et al. PROTECTIVE EFFECT OF NATURALLY ACQUIRED HOMOTYPIC AND HETEROTYPIC ROTAVIRUS ANTIBODIES , 1986, The Lancet.
[26] G. Zissis,et al. FAILURE OF LIVE, ATTENUATED ORAL ROTAVIRUS VACCINE , 1986, The Lancet.
[27] R. Glass,et al. Rotavirus: the major etiologic agent of severe infantile diarrhea may be controllable by a "Jennerian" approach to vaccination. , 1986, The Journal of infectious diseases.
[28] R. Chanock,et al. Reassortant rotaviruses as potential live rotavirus vaccine candidates , 1985, Journal of virology.
[29] G. Zissis,et al. PROTECTION OF INFANTS AGAINST ROTAVIRUS DIARRHOEA BY RIT 4237 ATTENUATED BOVINE ROTAVIRUS STRAIN VACCINE , 1984, The Lancet.
[30] T. Vesikari. Clinical trials of live oral rotavirus vaccines: the Finnish experience. , 1993, Vaccine.
[31] R. Bishop. Development of candidate rotavirus vaccines. , 1993, Vaccine.